mdanderson.org
Dec 11, 2024, 09:53
Liso-cel is a feasible and effective option for patients with R/R large B cell lymphoma – MD Anderson Cancer Center
MD Anderson Cancer Center shared a post on X:
“For patients with relapsed or refractory large B cell lymphoma and secondary central nervous system involvement, Lisocabtagene Maraleucel (liso-cel) is a feasible and effective option, our Dr. Sairah Ahmed reported at ASH24 this morning.”
More posts featuring MD Anderson Cancer Center.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 7, 2025, 04:00
Jan 6, 2025, 19:32
Jan 6, 2025, 19:23
Jan 6, 2025, 19:21
Jan 6, 2025, 19:13
Jan 6, 2025, 19:09
Jan 6, 2025, 17:15
Jan 6, 2025, 17:07
Jan 6, 2025, 16:37